Pharma Market Access Accelerated Access Review: no panacea for UK pharma What can the AAR do for the UK pharma industry, the health service and patients?
Articles Accelerating health technologies with NICE Office for Market... England's health watchdog launched its service to speed the delivery of new technologies in October 2015.
Articles Early access initiatives – one year on Both the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) launched new initiatives aimed at achieving earlier access to promising new medi
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
